PL377777A1 - Leczenie chorób połączeniami agonistów receptora alfa 7-nikotynowego i innych związków - Google Patents

Leczenie chorób połączeniami agonistów receptora alfa 7-nikotynowego i innych związków

Info

Publication number
PL377777A1
PL377777A1 PL377777A PL37777703A PL377777A1 PL 377777 A1 PL377777 A1 PL 377777A1 PL 377777 A PL377777 A PL 377777A PL 37777703 A PL37777703 A PL 37777703A PL 377777 A1 PL377777 A1 PL 377777A1
Authority
PL
Poland
Prior art keywords
alpha
diseases
combinations
compounds
treatment
Prior art date
Application number
PL377777A
Other languages
English (en)
Inventor
Jeffrey Wayne Corbett
Vincent Edward Groppi Jr.
Original Assignee
Pharmacia & Upjohn Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Company Llc filed Critical Pharmacia & Upjohn Company Llc
Publication of PL377777A1 publication Critical patent/PL377777A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL377777A 2002-12-11 2003-11-28 Leczenie chorób połączeniami agonistów receptora alfa 7-nikotynowego i innych związków PL377777A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43252702P 2002-12-11 2002-12-11

Publications (1)

Publication Number Publication Date
PL377777A1 true PL377777A1 (pl) 2006-02-20

Family

ID=32507947

Family Applications (1)

Application Number Title Priority Date Filing Date
PL377777A PL377777A1 (pl) 2002-12-11 2003-11-28 Leczenie chorób połączeniami agonistów receptora alfa 7-nikotynowego i innych związków

Country Status (12)

Country Link
US (1) US20050245504A1 (pl)
EP (1) EP1572205A2 (pl)
JP (1) JP2006510662A (pl)
KR (1) KR20050085535A (pl)
CN (1) CN1726033A (pl)
AU (1) AU2003279492A1 (pl)
BR (1) BR0317110A (pl)
CA (1) CA2508004A1 (pl)
MX (1) MXPA05005666A (pl)
PL (1) PL377777A1 (pl)
WO (1) WO2004052348A2 (pl)
ZA (1) ZA200503645B (pl)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
SE0202598D0 (sv) * 2002-09-02 2002-09-02 Astrazeneca Ab Alpha-7 Nicotinic receptor agonists and statins in combination
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
GB0310867D0 (en) 2003-05-12 2003-06-18 Novartis Ag Organic compounds
ZA200603165B (en) 2003-11-03 2007-07-25 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
KR101099206B1 (ko) 2004-02-05 2011-12-27 프로비오드룩 아게 신규한 글루타미닐 시클라제 저해제
NZ550534A (en) 2004-03-25 2009-07-31 Memory Pharm Corp Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
PE20060437A1 (es) * 2004-06-18 2006-06-08 Novartis Ag COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
EP1812007B1 (en) 2004-11-02 2011-09-07 Northwestern University Pyridazine compounds and methods
GB0521508D0 (en) * 2005-10-21 2005-11-30 Novartis Ag Organic compounds
GB0525673D0 (en) * 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525672D0 (en) * 2005-12-16 2006-01-25 Novartis Ag Organic compounds
PE20071143A1 (es) * 2006-01-13 2008-01-20 Wyeth Corp Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6
US8158627B2 (en) 2006-04-28 2012-04-17 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
FR2931677B1 (fr) * 2008-06-02 2010-08-20 Sanofi Aventis Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs
EP3357495B1 (en) 2008-11-19 2019-12-25 Axovant Sciences GmbH Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
US20100233156A1 (en) * 2009-03-09 2010-09-16 Georgetown University Treating Central Nervous System Injury with Beta and Gamma Secretase Inhibitors
MX2011011972A (es) * 2009-05-11 2011-12-08 Envivo Pharmaceuticals Inc Tratamiento de trastornos cognitivos con determinados receptores de acido nicotinico alfa-7 en combinacion con inhibidores de acetilcolinesterasa.
CN102905532A (zh) 2010-02-09 2013-01-30 约翰斯.霍普金斯大学 用于改善认知功能的方法和组合物
JP5749797B2 (ja) 2010-05-17 2015-07-15 フォルム ファーマシューティカルズ、インコーポレイテッド （ｒ）−７−クロロ−ｎ−（キヌクリジン−３−イル）ベンゾ［ｂ］チオフェン−２−カルボキサミド塩酸塩一水和物の結晶形
BR112013001939A2 (pt) * 2010-07-26 2017-07-11 Envivo Pharmaceuticals Inc tratamento de distúrbios cognitivos com determinados agonistas receptores de ácido alfa-7-nicotínico em combinação com inibidres de acetilcolinesterase
WO2013019901A2 (en) * 2011-08-02 2013-02-07 Buck Institute For Research On Aging Tropinol esters and related compounds to promote normal processing of app
AU2012321345B2 (en) * 2011-10-03 2016-03-17 The University Of Utah Research Foundation Application of 5-HT6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
WO2013169646A1 (en) 2012-05-08 2013-11-14 Envivo Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA
AU2014228512A1 (en) 2013-03-15 2015-10-01 Agenebio, Inc. Methods and compositions for improving cognitive function
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
WO2016100184A1 (en) * 2014-12-16 2016-06-23 Forum Pharmaceuticals, Inc. Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
CN112843005B (zh) 2015-05-22 2023-02-21 艾吉因生物股份有限公司 左乙拉西坦的延时释放药物组合物
RS63653B1 (sr) 2015-07-22 2022-11-30 Enanta Pharm Inc Benzodiazepinski derivati kao inhibitori rsv
RU2624978C2 (ru) * 2015-07-27 2017-07-11 Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежский государственный медицинский университет им. Н.Н. Бурденко" Министерства здравоохранения Российской Федерации Способ лечения умеренного когнитивного снижения
EP3897670A4 (en) 2018-12-19 2022-09-07 Disarm Therapeutics, Inc. MRSA1 INHIBITORS IN COMBINATION WITH NEUROPROTECTIVE AGENTS
SG11202110137VA (en) 2019-03-18 2021-10-28 Enanta Pharm Inc Benzodiazepine derivatives as rsv inhibitors
IL291834A (en) 2019-10-04 2022-06-01 Enanta Pharm Inc Heterocyclic antiviral compounds
US11505558B1 (en) 2019-10-04 2022-11-22 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
US11945824B2 (en) 2020-10-19 2024-04-02 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as anti-viral agents
CN112625057B (zh) * 2020-12-25 2022-12-09 山东金城柯瑞化学有限公司 3-羟基-4-((三甲基甲硅烷基)乙炔基)苯甲酸甲酯的合成方法
US11945830B2 (en) * 2021-02-26 2024-04-02 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904176D0 (sv) * 1999-11-18 1999-11-18 Astra Ab New use
SE0000540D0 (sv) * 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
AU2001282875A1 (en) * 2000-08-21 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
US6599916B2 (en) * 2000-08-21 2003-07-29 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
WO2002094768A2 (en) * 2001-05-22 2002-11-28 Elan Pharmaceuticals, Inc. Aza hydroxylated ethyl amine compounds
US20030236287A1 (en) * 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor

Also Published As

Publication number Publication date
WO2004052348A2 (en) 2004-06-24
BR0317110A (pt) 2005-10-25
EP1572205A2 (en) 2005-09-14
ZA200503645B (en) 2006-11-29
WO2004052348A3 (en) 2004-10-21
KR20050085535A (ko) 2005-08-29
AU2003279492A1 (en) 2004-06-30
US20050245504A1 (en) 2005-11-03
CA2508004A1 (en) 2004-06-24
MXPA05005666A (es) 2005-07-26
CN1726033A (zh) 2006-01-25
JP2006510662A (ja) 2006-03-30

Similar Documents

Publication Publication Date Title
ZA200503645B (en) Treatment of diseases with combinations of alpha 7 nicotinic acetylcholine receptor agonists and other compounds
AU2003223579A8 (en) Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease
TWI340640B (en) Combination, kit and pharmaceutical composition for treatment of parkinson's disease
EP1549614A4 (en) VASCULATORY AGENTS AND METHODS FOR THEIR APPLICATION
AU2003217870A8 (en) Pini-modulating compounds and methods of use thereof
EP1416961A4 (en) COMPOSITION AND METHOD FOR THE TREATMENT OF A DISEASE
EP1539210A4 (en) GLP-1 RECEPTOR MODIFIED AGONISTS AND THEIR PHARMACOLOGICAL METHODS OF USE
AU2003213673A8 (en) Pin1-modulating compounds and methods of use thereof
EP1570839A4 (en) COMPOSITION FOR PREPARATION FOR EXTERNAL APPLICATION TO THE SKIN AND METHOD FOR THE USE THEREOF
AU2003246102A8 (en) Method of examining allergic disease and drug for treating the same
EP1487446A4 (en) BICYCLIC HETEROCYCLES FOR THE TREATMENT OF DIABETES AND OTHER DISEASES
AU2003279442A8 (en) 2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes
AU2003290605A8 (en) Compositions and methods for the diagnosis and treatment of sepsis
EP1476150A4 (en) CARBOXY FULLERES AND USE METHOD THEREFOR
AU2003268295A8 (en) "diagnosis and treatment of infertility"
GB0212405D0 (en) Composition and its therapeutic use
EP1575497A4 (en) NEW COMPOSITION AND METHOD FOR TREATING PSORIASIS
GB0207410D0 (en) Compounds and their therapeutic use
PL375564A1 (pl) Podstawione 5-chroman-5-ylo-etyloaminy i ich zastosowanie do leczenia jaskry
IL162941A0 (en) Carboxamidine derivatives and their use in the treatment of vascular diseases
IL166062A0 (en) Compositions and methods for therapeutic treatment
EP1539100A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN DISORDERS
EP1483407A4 (en) THERAPY AND DIAGNOSTIC PROCEDURES
GB0207409D0 (en) Benzofuran-2H-3-one compounds and their therapeutic use
AU2002328173A1 (en) Omoxin agonists and antagonists for use in the treatment of metabolic disorders

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)